Aura Announces Global Phase 3 Trial Design with Suprachoroidal Route of Administration Based on Positive Phase 2 Interim Data of Belzupacap Sarotalocan in Early-Stage Choroidal Melanoma - Arix Bioscience

Close Navigation

About Strategy Team Portfolio Insights Media Contact

Overlay

Aura Announces Global Phase 3 Trial Design with Suprachoroidal Route of Administration Based on Positive Phase 2 Interim Data of Belzupacap Sarotalocan in Early-Stage Choroidal Melanoma

10th November 2022

Portfolio

This post references, or is about Aura. Find out more by clicking below

Video

Cambridge, USA

Useful Tools

Download, print or share this article

Print

Print Article Email

Email

Print

Share Article